115 related articles for article (PubMed ID: 9354234)
1. E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group.
Schaschke N; Assfalg-Machleidt I; Machleidt W; Turk D; Moroder L
Bioorg Med Chem; 1997 Sep; 5(9):1789-97. PubMed ID: 9354234
[TBL] [Abstract][Full Text] [Related]
2. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases.
Martichonok V; Plouffe C; Storer AC; Ménard R; Jones JB
J Med Chem; 1995 Aug; 38(16):3078-85. PubMed ID: 7636871
[TBL] [Abstract][Full Text] [Related]
3. Substrate/propeptide-derived endo-epoxysuccinyl peptides as highly potent and selective cathepsin B inhibitors.
Schaschke N; Assfalg-Machleidt I; Machleidt W; Moroder L
FEBS Lett; 1998 Jan; 421(1):80-2. PubMed ID: 9462845
[TBL] [Abstract][Full Text] [Related]
4. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B.
Gour-Salin BJ; Lachance P; Plouffe C; Storer AC; Ménard R
J Med Chem; 1993 Mar; 36(6):720-5. PubMed ID: 8459399
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors.
Zhang X; Yang X; Wang H; Li S; Guo K; Jiang D; Xiao J; Liang D
Biol Pharm Bull; 2017 Aug; 40(8):1240-1246. PubMed ID: 28502922
[TBL] [Abstract][Full Text] [Related]
7. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex.
Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T
Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902
[TBL] [Abstract][Full Text] [Related]
9. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
10. pH Dependence of inhibitors targeting the occluding loop of cathepsin B.
Cathers BE; Barrett C; Palmer JT; Rydzewski RM
Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705
[TBL] [Abstract][Full Text] [Related]
11. E64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane] analogues as inhibitors of cysteine proteinases: investigation of S2 subsite interactions.
Gour-Salin BJ; Lachance P; Magny MC; Plouffe C; Ménard R; Storer AC
Biochem J; 1994 Apr; 299 ( Pt 2)(Pt 2):389-92. PubMed ID: 8172599
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and SH-enzyme inhibitory activities of new epoxysuccinic acid piperazine derivatives against mu-calpain and cathepsin B.
Inoue J; Yoshida Y; Nakamura M; Cui YS; Nagao Y
Drug Des Discov; 1999 Aug; 16(2):165-9. PubMed ID: 10533812
[TBL] [Abstract][Full Text] [Related]
13. Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.
Fusetani N; Fujita M; Nakao Y; Matsunaga S; Van Soest RW
Bioorg Med Chem Lett; 1999 Dec; 9(24):3397-402. PubMed ID: 10617079
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors.
Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V
Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586
[TBL] [Abstract][Full Text] [Related]
15. Epoxysuccinyl peptide-derived cathepsin B inhibitors: modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin.
Schaschke N; Deluca D; Assfalg-Machleidt I; Höhneke C; Sommerhoff CP; Machleidt W
Biol Chem; 2002 May; 383(5):849-52. PubMed ID: 12108551
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of cysteine proteases.
Govardhan CP; Abeles RH
Arch Biochem Biophys; 1996 Jun; 330(1):110-4. PubMed ID: 8651683
[TBL] [Abstract][Full Text] [Related]
17. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
18. The binding mode of an E-64 analog to the active site of cathepsin B.
Feng MH; Chan SL; Xiang Y; Huber CP; Lim C
Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350
[TBL] [Abstract][Full Text] [Related]
19. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction.
Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective synthesis of E-64 and related cysteine proteases inhibitors from 2,3-epoxyamides.
Sarabia F; Sánchez-Ruiz A; Chammaa S
Bioorg Med Chem; 2005 Mar; 13(5):1691-705. PubMed ID: 15698787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
